VOL. 12, NO. 6 • JUNE 2019 Dear Colleagues: Welcome to the June 2019 issue of The Journal of Clinical and Aesthetic Dermatology (JCAD). In this issue, we are pleased
Dear Editor: Tofacitinib is a Janus kinase (JAK) 1/3 inhibitor that has been approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis, psoriatic arthritis,
J Clin Aesthet Dermatol. 2019;12(6):17–24 by James Q. Del Rosso, DO, FAOCD, FAAD; Emil Tanghetti, MD, FAAD; Guy Webster, MD, PhD, FAAD; Linda Stein Gold, MD, FAAD; Diane Thiboutot, MD,
J Clin Aesthet Dermatol. 2019;12(6):27–28 by Brooke Vasicek, MD; William Adams, PhD; Laryn Steadman, BFA; Jeave Reserva, MD; and James Swan, MD Drs. Vasicek, Reserva, and Swan are with the Division
J Clin Aesthet Dermatol. 2019;12(6):30–41 by James Q. Del Rosso, DO; Theodore Rosen, MD; Dimitry Palceski, DO; and Maria Jose Rueda, MD Dr. Del Rosso is with JDR Dermatology Research/Thomas
